Because Rheb1 is modified with farnesyl residues during activation and farnesylation is a necessary step for Rheb1 activity, inhibiting farnesylation by farnesyl transferase inhibitors (FTIs) could suppress active Rheb1-mediated neuropsychiatric disorders in TSC. Here, RHEBP1 is linked to tuberous sclerosis.